# A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

> **NCT02626754** · PHASE2 · TERMINATED · sponsor: **vghtpe user** · enrollment: 13 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Sunitinib malate

## Key facts

- **NCT ID:** NCT02626754
- **Lead sponsor:** vghtpe user
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-12
- **Primary completion:** 2018-01-02
- **Final completion:** 2018-01-02
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** In most sites had difficult to recruitting subjects.
- **Last updated:** 2018-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02626754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02626754, "A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02626754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*